Generic drugmakers have much thinner margins, and are less interested in “reshoring” to the US where the costs are higher.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
Despite its initial fumble with Google Glass, there are a few reasons it may be able to avoid another “glassholes” situation.
But Meta’s AI may have Snap’s beat “just in sheer volume” of data, one expert said.
Bloomberg reported on Wednesday that Meta is bleeding third-party augmented reality developers to its rival, Snap.